arrow
E

Eric W. Humke

Howard Hughes Medical Institute
H指数:21
被引数:3,289

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
2023-12-010
PRE
A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
2023-12-011
PRE
IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+T cell mediated cytotoxicity of PD-L1-positive tumor cells
2023-04-040
PRE
A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
2020-02-1513
PRE
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
2019-02-0449
OAAI
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Anti-NaPi2b抗体药物偶联物利法妥珠单抗维多汀 (DNIB0600A) 与聚乙二醇化脂质体多柔比星在铂类耐药卵巢癌患者中的随机,开放标签,II期研究

2018-04-0170
OAAI
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
2016-11-0183
OAAI